211 related articles for article (PubMed ID: 16682729)
1. Long-term follow-up after reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia/myelodysplastic syndrome: late CNS relapses despite graft-versus-host disease.
Davies JK; Taussig DC; Oakervee H; Davies AJ; Agrawal SG; Gribben JG; Lister TA; Cavenagh JD
J Clin Oncol; 2006 May; 24(14):e23-5. PubMed ID: 16682729
[No Abstract] [Full Text] [Related]
2. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
[TBL] [Abstract][Full Text] [Related]
3. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and acute myelogenous leukemia.
Valcárcel D; Martino R
Curr Opin Oncol; 2007 Nov; 19(6):660-6. PubMed ID: 17906468
[TBL] [Abstract][Full Text] [Related]
4. Long-term remissions in patients with myelodysplastic syndrome and secondary acute myelogenous leukemia undergoing allogeneic transplantation following a reduced intensity conditioning regimen of 550 cGy total body irradiation and cyclophosphamide.
Hallemeier CL; Girgis MD; Blum WG; Brown RA; Khoury HJ; Devine SM; Vij R; Lin HS; DiPersio JF; Adkins DR
Biol Blood Marrow Transplant; 2006 Jul; 12(7):749-57. PubMed ID: 16785064
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
6. Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome.
Alyea EP; Kim HT; Ho V; Cutler C; DeAngelo DJ; Stone R; Ritz J; Antin JH; Soiffer RJ
Biol Blood Marrow Transplant; 2006 Oct; 12(10):1047-55. PubMed ID: 17067911
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic transplantation for the elderly patient with acute myelogenous leukemia or myelodysplastic syndrome.
de Lima M; Giralt S
Semin Hematol; 2006 Apr; 43(2):107-17. PubMed ID: 16616044
[TBL] [Abstract][Full Text] [Related]
8. A prospective multicenter trial of peripheral blood stem cell sibling allografts for acute myeloid leukemia in first complete remission using fludarabine-cyclophosphamide reduced intensity conditioning.
Grigg AP; Gibson J; Bardy PG; Reynolds J; Shuttleworth P; Koelmeyer RL; Szer J; Roberts AW; To LB; Kennedy G; Bradstock KF
Biol Blood Marrow Transplant; 2007 May; 13(5):560-7. PubMed ID: 17448915
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic transplantation for myelodysplastic syndrome (MDS).
Ingram W; Lim ZY; Mufti GJ
Blood Rev; 2007 Mar; 21(2):61-71. PubMed ID: 16759774
[TBL] [Abstract][Full Text] [Related]
10. Hematopoietic stem cell transplantation after reduced intensity conditioning in acute myelogenous leukemia patients older than 40 years.
Huisman C; Meijer E; Petersen EJ; Lokhorst HM; Verdonck LF
Biol Blood Marrow Transplant; 2008 Feb; 14(2):181-6. PubMed ID: 18215778
[TBL] [Abstract][Full Text] [Related]
11. Reduced intensity conditioning allogeneic bone marrow transplantation following central nervous system (CNS) relapse of acute promyelocytic leukemia: evidence for a graft-versus-leukemia effect in the CNS.
Ostronoff M; Domingues MC; Ostronoff F; Matias C; Florêncio R; Matias K; Souto Maior AP; Sucupira A; Calixto R; Tagliari C
Am J Hematol; 2006 May; 81(5):387-8. PubMed ID: 16628719
[No Abstract] [Full Text] [Related]
12. Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome.
Nakamura R; Rodriguez R; Palmer J; Stein A; Naing A; Tsai N; Chang K; Slovak ML; Bhatia R; Spielberger R; Kogut N; Pullarkat V; Kirschbaum M; Forman SJ; O'Donnell MR
Bone Marrow Transplant; 2007 Nov; 40(9):843-50. PubMed ID: 17724447
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment of relapsed AML after allogeneic stem cell transplantation with azacitidine.
Graef T; Kuendgen A; Fenk R; Zohren F; Haas R; Kobbe G
Leuk Res; 2007 Feb; 31(2):257-9. PubMed ID: 16620971
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic hemopoietic stem cell transplants for patients with relapsed acute leukemia: long-term outcome.
Bacigalupo A; Lamparelli T; Gualandi F; Occhini D; Bregante S; Raiola AM; Ibatici A; di Grazia C; Dominietto A; Piaggio G; Podesta M; Bruno B; Lombardi A; Frassoni F; Viscoli C; Sacchi N; Van Lint MT
Bone Marrow Transplant; 2007 Mar; 39(6):341-6. PubMed ID: 17277788
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: long-term follow-up.
Shimoni A; Hardan I; Shem-Tov N; Yerushalmi R; Nagler A
Leukemia; 2010 May; 24(5):1050-2. PubMed ID: 20147978
[No Abstract] [Full Text] [Related]
16. Second allogeneic stem cell transplantation in myeloid malignancies.
Hartwig M; Ocheni S; Asenova S; Wiedemann B; Zabelina T; Ayuk F; Kabisch H; Erttmann R; Kröger N; Zander AR; Bacher U
Acta Haematol; 2009; 122(4):185-92. PubMed ID: 19887774
[TBL] [Abstract][Full Text] [Related]
17. GvHD-free, relapse-free survival after reduced-intensity allogeneic hematopoietic cell transplantation in older patients with myeloid malignancies.
Nazha A; Rybicki L; Abounader D; Bolwell B; Dean R; Gerds AT; Jagadeesh D; Hamilton BK; Hill BT; Kalaycio M; Liu H; Pohlman B; Sobecks R; Sekeres MA; Majhail NS
Bone Marrow Transplant; 2016 Dec; 51(12):1642-1643. PubMed ID: 27721371
[No Abstract] [Full Text] [Related]
18. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic stem cell transplantation for myelodysplastic syndrome.
Barrett AJ; Savani BN
Semin Hematol; 2008 Jan; 45(1):49-59. PubMed ID: 18179969
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic stem cell transplantation after reduced-intensity conditioning in a patient with T-cell prolymphocytic leukemia: graft-versus-tumor effect and long-term remission.
de Lavallade H; Faucher C; Fürst S; El-Cheikh J; Vey N; Coso D; Bouabdallah R; Stoppa AM; Gastaut JA; Blaise D; Mohty M
Bone Marrow Transplant; 2006 Apr; 37(7):709-10. PubMed ID: 16474410
[No Abstract] [Full Text] [Related]
[Next] [New Search]
